Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Transdermal system containing progestin
system containing progestin · 1 trial · 1 indication
The primary efficacy endpoint will be pregnancy rate described by Pearl Index (PI). PI is defined as the number of pregnancies per 100 women-years.
| Arm | Type | Description |
|---|---|---|
| This is a single-arm study. | EXPERIMENTAL | The study patch is a transdermal system that contains the active ingredient progestin. This study is an open-label, single-arm study. This means that all participants in the study will receive the study patch |
| Name | Type | Description |
|---|---|---|
| Transdermal system containing progestin | DRUG | MR-130A-01 transdermal system, patch to be used for female contraception |
Inclusion Criteria: 1. Healthy, post-menarcheal and premenopausal women at risk of pregnancy who are at least 16 years of age. 2. Desires to avoid pregnancy, is seeking to use hormonal contraception for at least 1 year. 3. Has negative UPT results at screening and at enrollment visits. 4. Has norma...
The system containing progestin is used for female contraception. It is a progestin-only patch being studied in women of childbearing potential. The drug is currently in Phase 3 clinical development and is not yet approved by the FDA.
Viatris Inc. (ticker: VTRS) is developing the system containing progestin. The company is conducting a Phase 3 clinical trial to evaluate the contraceptive efficacy and safety of this progestin-only patch in women of childbearing potential.
The system containing progestin is in Phase 3 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 3 trial is active but not recruiting participants.
The system containing progestin is being studied in one Phase 3 clinical trial, NCT06672016, titled 'Study to Evaluate Contraceptive Efficacy and Safety of a Progestin Only Patch in Women of Childbearing Potential.' The trial is active but not recruiting, with an enrollment of 1630 participants in the United States.
Yes, the system containing progestin is also known as the transdermal system containing progestin. It is a progestin-only patch being developed by Viatris Inc. for female contraception, currently in Phase 3 clinical trials.